Linical Co., Ltd.
TTSE:2183205.00
JPY
+2.00
(+0.99%)
ISIN
JP3974530002
Return %
Stock
S&P 500
1Y
-39.53
14.20
3Y
-64.78
81.12
5Y
-73.65
68.34
Capital Structure
JPY
•
in mil. unless spec.Working Capital
JPY
•
in mil. unless spec.Growth Rates
JPY
•
in mil. unless spec.Quarterly Revenue
JPY
•
in mil. unless spec.Quarterly Earnings Per Share
JPY
•
in mil. unless spec.Quarterly Dividends Per Share
JPY
•
in mil. unless spec.Company Description
- CEO
- Kazuhiro Hatano
- Full Time Employees
- 577
- Sector
- Commercial services
- Industry
- Miscellaneous commercial services
- Address
- Shin-Osaka Brick Building Osaka OS Japan 532-0003
- IPO Date
- Oct 29, 2008
- Website
- linical.co.jp
- Similar Companies
- Business
- Linical Co., Ltd. is a Japan-based contract research organization (CRO) specializing in comprehensive drug development services primarily in oncology, central nervous system, immunology, and other challenging therapeutic areas. The company provides a broad spectrum of clinical development offerings including clinical trial management from early to late phases; protocol development and study design; regulatory consulting; clinical monitoring; quality management and consulting; vendor management; auditing; data management; biostatistical analysis; medical writing; pharmacovigilance; and medical affairs. Linical operates globally with key markets in Japan, the United States, Europe, and Asia-Pacific, supporting pharmaceutical and biotech clients with integrated lifecycle management services and strategic consulting from drug discovery through post-marketing. Founded in 2005 and headquartered in Osaka, Japan, Linical also extends its operations through subsidiaries such as Linical Korea Co., Ltd. In the last 1-2 years, Linical has focused on strategic global expansion with heightened investment in the United States and digital transformation through AI and digital tools to enhance operational efficiency. The company aims to be a leading global mid-sized CRO by expanding geographical presence to approximately 60 countries and increasing capacity for large-scale, multinational clinical trials, emphasizing oncology and neurology fields. It has reinforced its role as a strategic partner with biopharma clients by evolving its business model toward knowledge-intensive, high-profitability services. Linical furthers its commitment to innovation by expanding contract medical affairs, regulatory affairs consultation, and drug lifecycle support services. It pursues growth through investment and potential M&A activity to strengthen global operations and service offerings. Linical’s key service portfolio includes drug development consulting; clinical trial planning, monitoring, and execution; quality control; regulatory and compliance support; post-authorization studies; and comprehensive pharmacovigilance. The company's global network and multi-therapeutic expertise enable it to deliver high-quality clinical data with speed and flexibility for diverse clients, ranging from major pharmaceutical companies to promising biotech firms. Linical continues to reinforce its profitability and sustainable growth by targeting operational efficiencies and expanding its footprint in critical global markets, including a strong presence in the U.S. and Asia regions. Its strategic vision emphasizes becoming the strongest CRO by delivering value through knowledge-intensive services and fostering long-term client partnerships.